It seems institutional shareholders are waiting for this EFS IDE to complete its process making sure it results in an Authorized FDA Pivotal Study or something close to it like the Traditional EFS IDE. Many will be reading into any FDA comments from it to qualify it for a big investment. Im surprised RDGL has not received more attention but its going to get juicier real soon. $RDGL
News 
Market Data 
Discover 
